and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

Other Events. On March 19, the Company issued a press release announcing that the Board of Directors (the “Board”) of Niagen Bioscience, Inc. (the “Company”) approved an increase in the authorization under the Company’s share repurchase program. Under the amended authorization, the Company may repurchase up to $20.0 million of its outstanding common stock, representing an increase from the previously authorized $10.0 million share repurchase program approved by the Board on October 31, 2025.…

in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Other Events. On February 24, 2026, ChromaDex, Inc. and ChromaDex Analytics, Inc., each a wholly-owned subsidiary of the Company, and the Company, as guarantor of certain provisions (together with ChromaDex, Inc. and ChromaDex Analytics, Inc., the “Sellers”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with VHG Labs, Incorporated, part of LGC Group (the “Buyer”), pursuant to which the Sellers agreed to sell substantially all of the assets comprising the Sellers’ analyt…

Entry into a Material Definitive Agreement. On December 18, 2025, ChromaDex, Inc. (the “Company”), a wholly owned subsidiary of Niagen Bioscience, Inc. (the “Registrant”), executed an assignment agreement (the “Agreement”) with Queen’s University Belfast (“QUB”), with an effective date of December 16, 2025. The Agreement replaces the parties’ existing intellectual property arrangements pursuant to the Joint Ownership and Management Agreement, dated October 9, 2015, as amended (the “JOMA”), an…

Other Events. On November 6, 2025, the Company issued a press release announcing that the Board of Directors (the “Board”) of Niagen Bioscience, Inc. (the “Company”) approved a share repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $10.0 million of its common stock. Repurchases of the Company’s outstanding common stock will be made in accordance with applicable securities laws and at such times, in such manner, prices and amounts as determined by…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On July 25, 2025, ChromaDex, Inc. (the “Company”), a wholly owned subsidiary of Niagen Bioscience, Inc., executed a Sales Agreement (the “Supply Agreement”) with W. R. Grace & Co.-Conn (“Grace”), a Connecticut corporation, with an effective date of April 1, 2025. Pursuant to the Supply Agreement, Grace will exclusively supply the Company with Nicotinamide-beta-Riboside Chloride (“NRCL”) meeting certain specifications as defined in a previously execu…

The filing is about the approval of an amendment to the equity incentive plan and the approval of an employee stock purchase plan, which are not management changes.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Robert Fried: Amendment to Mr. Fried's employment agreement and grant of performance stock units.

Changes in Registrant’s Certifying Accountant. Following a competitive request-for-proposal process during which the Audit Committee of our Board of Directors (the “Audit Committee”) solicited and reviewed proposals from several accounting firms, the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, effective December 13, 2024. During the Company's two most recent fiscal y…

Entry into a Material Definitive Agreement. On November 20, 2024, ChromaDex Corporation (the “Company”) entered into an amendment (the “Amendment”) to the At Market Issuance Sales Agreement, dated as of June 12, 2020 (the “Sales Agreement”) governing the Company’s “at-the-market” equity offering program for its common stock, par value $0.001 per share, in order to (i) revise the list of Sales Agents under the program to include Roth Capital Partners, LLC (“Roth Capital Partners”), (ii) remove…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

Changes in Registrant’s Certifying Accountant. On October 8, 2024, Marcum LLP (“Marcum”) notified ChromaDex Corporation (the “Company”) that it was resigning, effective October 31, 2024, as the independent registered public accounting firm for the Company due to independence concerns relating to Marcum’s impending merger with CBIZ Inc., which provides human resources consulting and health insurance brokerage services to the Company. Marcum is not required to obtain, and did not seek, the Comp…

Chief Financial Officer and Principal Accounting Officer — Ozan Pamir: ChromaDex Corporation appointed Ozan Pamir as the Chief Financial Officer and Principal Accounting Officer, replacing interim CFO James Lee.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

Interim Chief Financial Officer and Interim Principal Accounting Officer — James Lee: James Lee was promoted to Interim Chief Financial Officer and Interim Principal Accounting Officer following the resignation of Brianna Gerber.

Chief Financial Officer and Chief Accounting Officer — Brianna Gerber: Ms. Brianna Gerber is resigning from her roles as Chief Financial Officer and Chief Accounting Officer.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under